ArticleFrontiers in immunology2026
A bibliometric analysis of resistance to PD-1/PD-L1 inhibitors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Programmed cell death protein 1 (PD-1) or Programmed death-ligand 1 (PD-L1) inhibitors have already reformed cancer treatment by inhibiting tumor immune escape. However, as drug resistance emerges, their clinical application is limited. Numerous studies have explored mechanisms and methods to address resistance, yet an explicit bibliometric analysis of this field remains lacking. Methods: We systematically retrieved documents from the Web of Science Core Collection database and Scopus database. The timeline spans from January 1, 2006, to November 29, 2025. A comprehensive analysis was conducted using bibliometric tools. In addition, a secondary screening of the included studies was conducted to classify and analyze them based on their experimental models. Results: The bibliometric analysis of 2,122 studies shows a significant increase in research on resistance to PD-1/PD-L1 inhibitors from 2006 to 2025. China leads in publication volume, while the United States ranks second but has more international collaboration. Institutions such as Memorial Sloan Kettering Cancer Center are at the forefront of this research. The Conclusion: This study examines the academic background and hotspots in PD-1/PD-L1 resistance. In the future, the tumor microenvironment will be explored to uncover novel mechanisms of resistance and to identify predictive biomarkers for patient stratification, while combination therapy strategies will be applied to overcome therapeutic resistance. More randomized controlled trials (RCTs) and research on patient-derived organoid systems are needed to accelerate clinical translation. By illuminating future trends, this study will serve as a crucial reference for scholars seeking to advance the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.